Jun 29, 2022
BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of
Change | |
Volume |
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Copyright © VectivBio AG, 2022. All Rights Reserved.